Advertisement

Molecular Diagnosis & Therapy

, Volume 15, Issue 4, pp 235–245 | Cite as

Journal Watch

News

Contents

  • 1. Highlights from Adis Journals

  • 1.1 Cancer

  • 1.2 Cardiovascular Disorders

  • 1.3 Immunologic Disorders

  • 1.4 Infectious Diseases

  • 1.5 Psychiatric Disorders

  • 1.6 Skin Disorders

  • 1.7 Transplantation

  • 2. News from Other Sources

  • 2.1 News from the American Society of Clinical Oncology

  • 2.2 News from the International Society For Pharmacoeconomics and Outcomes Research

  • 2.3 Other News

1. Highlights from Adis Journals

1.1 Cancer

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on 4-Anilinoquinazolines

The 4-anilinoquinazolines (gefitinib, erlotinib, and lapatinib) are members of a class of potent and selective inhibitors of the human epidermal growth factor receptor (HER) family of tyrosine kinases, which have been developed to treat patients with tumors with defined genetic alterations of the HER tyrosine kinase domain. They are characterized by a moderate rate of absorption after oral administration with peak plasma concentrations at several hours post-dose. Absolute...

Reference

  1. Scheffler M, Di Gion P, Doroshyenko O, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 2011; 50(6): 371–403PubMedCrossRefGoogle Scholar

Reference

  1. Breccia M, Alimena G. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. BioDrugs 2011; 25(3): 147–57PubMedCrossRefGoogle Scholar

Reference

  1. Natarajan N, Telang S, Miller D, et al. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 2011; 71(10): 1233–50PubMedCrossRefGoogle Scholar

Reference

  1. Kalachand R, Hennessy BT, Markman M. Molecular targeted therapy in ovarian cancer: what is on the horizon? Drugs 2011; 71(8): 947–67PubMedCrossRefGoogle Scholar

Reference

  1. Montero A, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs 2011; 71(11): 1385–96PubMedCrossRefGoogle Scholar

Reference

  1. Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs 2011; 11(3): 145–52PubMedCrossRefGoogle Scholar

Reference

  1. Carreau V, Girardet JP, Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability. Pediatr Drugs 2011; 13(4): 267–75CrossRefGoogle Scholar

Reference

  1. Deneer VHM, vanHemel NM. Is antiarrhythmic treatment in the elderly different? A review of the specific changes. Drugs Aging 2011; 28(8): 617–33PubMedCrossRefGoogle Scholar

Reference

  1. Beresford MW. Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Pediatr Drugs 2011; 13(3): 161–73CrossRefGoogle Scholar

Reference

  1. Ding Q, Luckhardt T, Hecker L, et al. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs 2011; 71(8): 981–1001PubMedCrossRefGoogle Scholar

Reference

  1. Parra J, Portilla J, Pulido F, et al. Clinical utility of maraviroc. Clin Drug Investig 2011; 31(8): 527–42PubMedCrossRefGoogle Scholar

Reference

  1. Nadel S. Genetic susceptibility in sepsis: implications for the pediatric population. Pediatr Drugs 2011; 13(4): 205–8CrossRefGoogle Scholar

Reference

  1. Yang S, Khera P, Wahlgren C, et al. Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Am J Clin Dermatol 2011; 12(3): 203–9PubMedCrossRefGoogle Scholar

Reference

  1. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12(4): 259–70PubMedCrossRefGoogle Scholar

Reference

  1. Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin Pharmacokinet 2011; 50(7): 451–9PubMedCrossRefGoogle Scholar

References

  1. 1.
    Schneider BP, Li L, Miller K, et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103 [abstract no. 1000]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78499 [Accessed 2011 Aug 9]
  2. 2.
    American Society of Clinical Oncology. Predictive biomarker for taxane-induced neuropathy identified. ASCO Daily News [online]. Available from URL: http://chicago2011.asco.org/ASCODailyNews/genomics.aspx [Accessed 2011 Aug 9]
  3. 3.
    Yardley DA, Hainsworth JD, Harwin WN, et al. TITAN: ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): preliminary toxicity of a Sarah Cannon Research Institute phase III trial [abstract no. 1103]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81708 [Accessed 2011 Aug 9]
  4. 4.
    Inno A, Strippoli A, Nazzicone G, et al. Treatment of HER2-negative metastatic breast cancer (MBC) with bevacizumab (BEV) plus paclitaxel (TXL): a single-center phase II study [abstract no. e11509]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83730 [Accessed 2011 Aug 9]
  5. 5.
    Domchek SM, Friebel T, Neuhausen SL, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? [abstract no. 1501]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=78834 [Accessed 2011 Aug 9]
  6. 6.
    American Society of Clinical Oncology. Study suggests no increased breast cancer risk with hormone replacement therapy after risk-reducing salpingo-oophorectomy. ASCO Daily News [online]. Available from URL: http://chicago2011.asco.org/ASCODailyNews/Abstract1501.aspx [Accessed 2011 Aug 9]
  7. 7.
    Goss PE, Ingle JN, Ales-Martinez J, et al. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3 — a randomized, placebo-controlled clinical trial [abstract no. LBA504]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84784 [Accessed 2011 Aug 9]
  8. 8.
    Crook JM, O’Callaghan CJ, Ding K, et al. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013) [abstract no. 4514]. J Clin Oncol 2011; 29 Suppl. [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=77775 [Accessed 2011 Aug 9]
  9. 9.
    American Society of Clinical Oncology. Intermittent androgen suppression noninferiority could change treatment of localized prostate cancer. ASCO Daily News [online]. Available from URL: http://chicago2011.asco.org/ASCODailyNews/Abstract4514.aspx [Accessed 2011 Aug 9]

References

  1. 1.
    de Lima Lopes G. Epidermal growth factor receptor (EGFR) mutation testing and first line treatment with gefitinib is a dominant strategy in the treatment of advanced non-small cell lung cancer (NSCLC) [abstract no. PCN63]. Value Health 2011; 14(3): A166 [online]. Available from URL: http://www.ispor.org/publications/value/JVAL_14-3_final%204-26-2011.pdf [Accessed 2011 Aug 9]Google Scholar
  2. 2.
    Chen W, Ellis P, Levin L, et al. Cost-effectiveness of epidermal growth factor receptor gene mutation testing in the selection of first-line therapy for patients with advanced non-small cell lung cancer in Ontario [abstract no. PMD19]. Value Health 2011; 14(3): A82 [online]. Available from URL: http://www.ispor.org/publications/value/JVAL_14-3_final%204-26-2011.pdf [Accessed 2011 Aug 9]CrossRefGoogle Scholar
  3. 3.
    Paulden M, Franek J, Pham B, et al. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: a cost-effectiveness analysis of 1000 strategies for the provision of Adjuvant! Online, Oncotype DX and chemotherapy [abstract no. PCN72]. Value Health 2011; 14(3): A167 [online]. Available from URL:http://www.ispor.org/publications/value/JVAL_14-3_final%204-26-2011.pdf [Accessed 2011 Aug 9]CrossRefGoogle Scholar

Reference

  1. Australian Government Department of Health and Ageing. Erbitux and other new medicines listed on the PBS [media release]. 2011 Jun 21 [online]. Available from URL: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/mr-yr11-nr-nr123.htm [Accessed 2011 Aug 9]

Reference

  1. European Medicines Agency. European Medicines Agency recommends restricting use of Pandemrix [media release]. 2011 Jul 21 [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/human_pha_detail_000034.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d126 [Accessed 2011 Aug 9]

Reference

  1. US FDA. FDA drug safety communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm [Accessed 2011 Aug 9]

Copyright information

© Adis Data Information BV 2011

Personalised recommendations